Trials / Completed
CompletedNCT01653314
Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers
A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Megavec 400 mg (Imatinib Mesylate) Under Fasted Conditions in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg (Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Megavec | |
| DRUG | Glivec |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2012-07-31
- Last updated
- 2012-07-31
Source: ClinicalTrials.gov record NCT01653314. Inclusion in this directory is not an endorsement.